The efficacy of a single-dose anakinra injection during disease attack in pediatric familial Mediterranean fever.
Anakinra
Familial Mediterranean fever
Interleukin 1 receptor antagonist protein
On demand
Therapeutics
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
06 Jun 2023
06 Jun 2023
Historique:
received:
27
04
2023
accepted:
25
05
2023
medline:
6
6
2023
pubmed:
6
6
2023
entrez:
5
6
2023
Statut:
aheadofprint
Résumé
The aim of this retrospective study is to evaluate the efficacy of a single-dose anakinra during familial Mediterranean fever (FMF) attacks and its effect on the duration, severity, and frequency of attacks. The patients with FMF who had disease episode and received a single-dose anakinra during disease episode between December 2020 and May 2022 were included. Demographic characteristics, MEFV gene variants detected, concomitant medical conditions, demographics of recent and previous episodes, laboratory findings and length of hospital stay were recorded. A retrospective analysis of medical records revealed 79 attacks from 68 patients who met inclusion criteria. The patients had a median age of 13 (2.5-25) years. All patients reported that the average duration of their previous episodes lasted longer than 24 h. When the recovery time of attacks after subcutaneous anakinra application at the disease attack was examined, it was observed that 4 attacks (5.1%) ended in 10 min; 10 attacks (12.7%) in 10-30 min; 29 attacks (36.7%) in 30-60 min; 28 attacks (35.4%) in 1-4 h; 4 attacks (5.1%) in 24 h; and 4 attacks (5.1%) ended in more than 24 h. There was no patient who did not recover from their attack after a single dose of anakinra. Although the efficacy of a single-dose anakinra administration during FMF attacks in children needs to be confirmed by prospective studies, our results suggest that use of a single-dose anakinra during FMF attacks is effective in reduction of severity and duration of disease attacks.
Identifiants
pubmed: 37277620
doi: 10.1007/s00296-023-05351-0
pii: 10.1007/s00296-023-05351-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Yıldız M, Haşlak F, Adrovic A, Barut K, Kasapçopur Ö (2020) Autoinflammatory diseases in childhood. Balk Med J 37(5):236–246. https://doi.org/10.4274/balkanmedj.galenos.2020.2020.4.82
doi: 10.4274/balkanmedj.galenos.2020.2020.4.82
Ozdogan H, Ugurlu S (2019) Familial Mediterranean fever. Presse Med 48(1 Pt 2):e61–e76. https://doi.org/10.1016/j.lpm.2018.08.014
doi: 10.1016/j.lpm.2018.08.014
pubmed: 30686512
Alghamdi M (2017) Familial Mediterranean fever, review of the literature. Clin Rheumatol 36(8):1707–1713. https://doi.org/10.1007/s10067-017-3715-5
doi: 10.1007/s10067-017-3715-5
pubmed: 28624931
Demirkaya E, Erer B, Ozen S, Ben-Chetrit E (2016) Efficacy and safety of treatments in Familial Mediterranean fever: a systematic review. Rheumatol Int 36(3):325–331. https://doi.org/10.1007/s00296-015-3408-9
doi: 10.1007/s00296-015-3408-9
pubmed: 26687683
Gül A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, Sevgi S (2015) Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthr Res Ther 17(1):243. https://doi.org/10.1186/s13075-015-0765-4
doi: 10.1186/s13075-015-0765-4
Poddighe D, Romano M, Garcia-Bournissen F, Demirkaya E (2022) Conventional and novel therapeutic options in children with familial Mediterranean fever: a rare autoinflammatory disease. Br J Clin Pharmacol 88(6):2484–2499. https://doi.org/10.1111/bcp.15149
doi: 10.1111/bcp.15149
pubmed: 34799863
Sozeri B, Kasapcopur O (2015) Biological agents in familial Mediterranean fever focusing on colchicine resistance and amyloidosis. Curr Med Chem 22(16):1986–1991. https://doi.org/10.2174/0929867322666150311152300
doi: 10.2174/0929867322666150311152300
pubmed: 25760087
Holzinger D, Kessel C, Omenetti A, Gattorno M (2015) From bench to bedside and back again: translational research in autoinflammation. Nat Rev Rheumatol 11(10):573–585. https://doi.org/10.1038/nrrheum.2015.79
doi: 10.1038/nrrheum.2015.79
Giat E, Ben-Zvi I, Lidar M, Livneh A (2022) The preferential use of anakinra in various settings of FMF: a review applied to an updated treatment-related perspective of the disease. Int J Mol Sci. https://doi.org/10.3390/ijms23073956
doi: 10.3390/ijms23073956
pubmed: 35409316
pmcid: 8999740
Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, Ozdogan H, Abu I, Gattorno M, Hawkins PN, Yuce S, Kallinich T, Bilginer Y, Kastner D, Carmona L (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651. https://doi.org/10.1136/annrheumdis-2015-208690
doi: 10.1136/annrheumdis-2015-208690
pubmed: 26802180
Cetin P, Sari I, Sozeri B, Cam O, Birlik M, Akkoc N, Onen F, Akar S (2015) Efficacy of interleukin-1 targeting treatments in patients with familial Mediterranean Fever. Inflammation 38(1):27–31. https://doi.org/10.1007/s10753-014-0004-1
doi: 10.1007/s10753-014-0004-1
pubmed: 25139580
Sag E, Akal F, Atalay E, Akca UK, Demir S, Demirel D, Batu ED, Bilginer Y, Ozen S (2020) Anti-IL1 treatment in colchicine-resistant paediatric FMF patients: real life data from the HELIOS registry. Rheumatology (Oxford) 59(11):3324–3329. https://doi.org/10.1093/rheumatology/keaa121
doi: 10.1093/rheumatology/keaa121
pubmed: 32306038
Sezer M, Çelikel E, Tekin ZE, Güngörer V, Tekgöz N, Karagöl C, Coşkun S, Kaplan MM, Öner N, Polat MC, Sezer S, Acar B (2023) Assessment of quality of life, school performance and physical activity in adolescents with familial Mediterranean Fever. Mod Rheumatol. https://doi.org/10.1093/mr/road022
Yildirim DG, Bakkaloglu SA, Acar ASS, Celik B, Buyan N (2021) Evaluation of quality of life and its associations with clinical parameters in pediatric patients with familial Mediterranean fever. North Clin Istanb 8(3):255–260. https://doi.org/10.14744/nci.2020.90093
Ozen S, Bilginer Y (2014) A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 10(3):135–147. https://doi.org/10.1038/nrrheum.2013.174
doi: 10.1038/nrrheum.2013.174
pubmed: 24247370
Deger SM, Ozturk MA, Demirag MD, Aslan S, Goker B, Haznedaroglu S, Onat AM (2011) Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients. Rheumatol Int 31(5):623–628. https://doi.org/10.1007/s00296-009-1334-4
doi: 10.1007/s00296-009-1334-4
pubmed: 20049448
Lee A, Blair HA (2021) Anakinra in familial Mediterranean fever: a profile of its use. Drugs Ther Perspect 37(3):101–107. https://doi.org/10.1007/s40267-020-00807-w
doi: 10.1007/s40267-020-00807-w
Mercan R, Turan A, Bitik B, Tufan A, Haznedaroglu S, Goker B (2016) Rapid resolution of protracted febrile myalgia syndrome with anakinra: Report of two cases. Mod Rheumatol 26(3):458–459. https://doi.org/10.3109/14397595.2014.882221
doi: 10.3109/14397595.2014.882221
pubmed: 24533541
Tombetti E, Mulè A, Tamanini S, Matteucci L, Negro E, Brucato A, Carnovale C (2020) Novel Pharmacotherapies for recurrent pericarditis: current options in 2020. Curr Cardiol Rep 22(8):59. https://doi.org/10.1007/s11886-020-01308-y
doi: 10.1007/s11886-020-01308-y
pubmed: 32562029
pmcid: 7303578
Şahin A, Derin ME, Albayrak F, Karakaş B, Karagöz Y (2020) Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever. Adv Rheumatol 60(1):12. https://doi.org/10.1186/s42358-020-0117-1
doi: 10.1186/s42358-020-0117-1
pubmed: 32000860
Babaoglu H, Varan O, Kucuk H, Atas N, Satis H, Salman R, Ozturk MA, Haznedaroglu S, Goker B, Tufan A (2019) On demand use of anakinra for attacks of familial Mediterranean fever (FMF). Clin Rheumatol 38(2):577–581. https://doi.org/10.1007/s10067-018-4230-z
doi: 10.1007/s10067-018-4230-z
pubmed: 30062447
Yalçinkaya F, Ozen S, Ozçakar ZB, Aktay N, Cakar N, Düzova A, Kasapçopur O, Elhan AH, Doganay B, Ekim M, Kara N, Uncu N, Bakkaloglu A (2009) A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 48(4):395–398. https://doi.org/10.1093/rheumatology/ken509
doi: 10.1093/rheumatology/ken509
pubmed: 19193696
Demirkaya E, Saglam C, Turker T, Koné-Paut I, Woo P, Doglio M, Amaryan G, Frenkel J, Uziel Y, Insalaco A, Cantarini L, Hofer M, Boiu S, Duzova A, Modesto C, Bryant A, Rigante D, Papadopoulou-Alataki E, Guillaume-Czitrom S, Kuemmerle-Deschner J, Neven B, Lachmann H, Martini A, Ruperto N, Gattorno M, Ozen S (2016) Performance of different diagnostic criteria for familial Mediterranean Fever in children with periodic fevers: results from a multicenter international registry. J Rheumatol 43(1):154–160. https://doi.org/10.3899/jrheum.141249
doi: 10.3899/jrheum.141249
pubmed: 26568587
Lachmann HJ (2017) Periodic fever syndromes. Best Pract Res Clin Rheumatol 31(4):596–609. https://doi.org/10.1016/j.berh.2017.12.001
doi: 10.1016/j.berh.2017.12.001
pubmed: 29773275
La Regina M, Ben-Chetrit E, Gasparyan AY, Livneh A, Ozdogan H, Manna R (2013) Current trends in colchicine treatment in familial Mediterranean fever. Clin Exp Rheumatol 31(3 Suppl 77):41–46
pubmed: 24064013
Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F (2016) Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol 35(2):441–446. https://doi.org/10.1007/s10067-014-2772-2
doi: 10.1007/s10067-014-2772-2
pubmed: 25213327
Turkish FMF Study Group (2005) Familial Mediterranean Fever (FMF) in Turkey: results of a Nationwide Multicenter Study. Medicine 84(1):1–11
doi: 10.1097/01.md.0000152370.84628.0c
Barut K, Sahin S, Adrovic A, Sinoplu AB, Yucel G, Pamuk G, Aydın AK, Dasdemir S, Turanlı ET, Buyru N, Kasapcopur O (2018) Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int 38(1):67–74. https://doi.org/10.1007/s00296-017-3796-0
doi: 10.1007/s00296-017-3796-0
pubmed: 28828621
De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G (2018) Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med 378(20):1908–1919. https://doi.org/10.1056/NEJMoa1706314
doi: 10.1056/NEJMoa1706314
pubmed: 29768139
Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ, Kastner DL (2006) The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 103(26):9982–9987. https://doi.org/10.1073/pnas.0602081103
doi: 10.1073/pnas.0602081103
pubmed: 16785446
pmcid: 1479864
Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivity S, Perski O, Bornstein G, Grossman C, Harari G, Lidar M, Livneh A (2017) Anakinra for colchicine-resistant familial Mediterranean Fever: a randomized, double-blind, Placebo-contolled trial. Arthr Rheumatol 69(4):854–862. https://doi.org/10.1002/art.39995
doi: 10.1002/art.39995
Pecher AC, Igney-Oertel A, Kanz L, Henes J (2017) Treatment of familial Mediterranean fever with anakinra in patients unresponsive to colchicine. Scand J Rheumatol 46(5):407–409. https://doi.org/10.1080/03009742.2016.1245780
doi: 10.1080/03009742.2016.1245780
pubmed: 28097903
Avar Aydın P, Özçakar ZB, Aydın F, Karakaş HD, Çakar N, Yalçınkaya F (2022) The characteristics of pediatric patients with familial Mediterranean Fever treated with anti-interleukin-1 treatment. Turk Arch Pediatr 57(4):448–452. https://doi.org/10.5152/TurkArchPediatr.2022.22039
doi: 10.5152/TurkArchPediatr.2022.22039
pubmed: 35822478
pmcid: 9317639
Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A, Frenkel J (2011) On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 70(12):2155–2158. https://doi.org/10.1136/ard.2011.149922
doi: 10.1136/ard.2011.149922
pubmed: 21859689
Grimwood C, Despert V, Jeru I, Hentgen V (2015) On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Rheumatology (Oxford) 54(9):1749–1751. https://doi.org/10.1093/rheumatology/kev111
doi: 10.1093/rheumatology/kev111
pubmed: 26078218